IBMX (28822-58-4) is a pan-specific inhibitor of phosphodiesterases (IC50=2-50 µM). Inhibition of PDEs leads to increased concentration of intracellular cAMP which activates PKA2. IBMX does not inhibit PDE8 or PDE93. Weak adenosine receptor antagonist4.
References/Citations for IBMX
1) Beavo et al. (1970), Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase activity; Mol. Pharmacol., 6 597
2) Tomes et al. (1993), Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity; Cell Signal., 5 615
3) Soderling et al. (2000), Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions; Curr. Opin. Cell Biol., 12 174
4) Daly et al. (1987), Adenosine receptors: development of selective agonists and antagonists; Prog. Clin. Biol. Res., 230 41